United States: Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb) - Goodwin Procter LLP

Mondaq

31 Oct 2023 0 shares 1 views

United States: Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb) - Goodwin Procter LLP

Mondaq

Published 31 Oct 2023

On October 23, 2023, Celltrion announced FDA approval for ZYMFENTRA, a subcutaneous formulation for maintenance therapy for patients with moderately to severely active ulcerative colitis ...

Full Article

United States: Biogen Announces FDA Approval Of TOFIDENCE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

On September 29, 2023, Biogen announced the FDA approval of TOFIDENCE (tocilizumab-bavi) intravenous formulation which is the first..

Mondaq 06 Oct 2023

United States: Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb) - Goodwin Procter LLP

United States: Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb) - Goodwin Procter LLP

You might like

Related news coverage

United States: Biogen Announces FDA Approval Of TOFIDENCE, A Tocilizumab Biosimilar Referencing ACTEMRA - Goodwin Procter LLP

Advertisement